RT Journal Article
SR Electronic
T1 Genome sequencing combining prenatal ultrasound in the evaluation of fetal CNS structural anomalies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.04.20031294
DO 10.1101/2020.03.04.20031294
A1 Yang, Ying
A1 Zhao, Sheng
A1 Sun, Guoqiang
A1 Chen, Fang
A1 Zhang, Tongda
A1 Song, Jieping
A1 Yang, Wenzhong
A1 Wang, Lin
A1 Zhan, Nianji
A1 Yang, Xiaohong
A1 Zhu, Xia
A1 Rao, Bin
A1 Yin, Zhenzhen
A1 Zhou, Jing
A1 Yan, Haisheng
A1 Huang, Yushan
A1 Ye, Jingyu
A1 Huang, Hui
A1 Cheng, Chen
A1 Zhu, Shida
A1 Guo, Jian
A1 Xu, Xun
A1 Chen, Xinlin
YR 2020
UL http://medrxiv.org/content/early/2020/03/06/2020.03.04.20031294.abstract
AB Purpose Genome sequencing (GS) is potentially the most suitable diagnostic tools for fetal CNS structural anomalies. However, its efficacy hasn’t been proved in large cohort of fetal CNS structural anomalies.Methods Patients were enrolled by a multiple-level referral system when fetal CNS structure anomalies were found by ultrasonography. Samples from fetuses were subjected to GS.Results Data of 162 fetuses with 11 frequent types of CNS anomalies was collected. The overall diagnosis yield of GS was 38.9%. 36(20.3%) fetuses were detected with chromosomal anomalies and pathogenic CNVs. Pathogenic or likely pathogenic single-gene variants and intragenic CNVs were found in 24 and three fetuses, contributing 14.8% and 1.9% diagnostic yield respectively. The diagnostic rate in 41 fetuses with CNS malformation combined with anomalies out of brain was as high as 73.3%. Malformations of the posterior cerebral fossa, abnormal neuronal proliferation and migration have the highest diagnostic rates. NTDs had the second lowest diagnostic rates of 14.7% and none pathogenic variants were found in ultrasound anomalies that suggested destructive cerebral lesions.Conclusion GS is an efficient genetic testing tool with the diagnostic power compared to current CMA plus ES procedure in fetal CNS anomalies evaluation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project is mainly supported internally by BGI-Shenzhen. It is also supported by Science, Technology and Innovation Commission of Shenzhen Municipality under grant No. JCYJ20180703093402288, Department of Science and Technology of Guangdong Province under grants No. 2019B020227001, Natural Science Foundation of Hubei Province (2017CFB789) and Innovation Team Project of Health commission of Hubei Province (WJ2018H0132). Sequencing data was produced by China National Genebank. We are also grateful to BGI-Wuhan for helping transferring samples.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data reported in this study are available in the CNGB Nucleotide Sequence Archive (CNSA: CNP0000415). https://db.cngb.org/cnsa/